Recently several randomized controlled trials have demonstrated that two classes of glucose-lowering medications, glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), have shown a significant protective effect on CVD or CKD in T2D patients (3–5). Here, GLP1R is linked to chronic kidney disease.